公司资料
Madrigal 股价、新闻与催化剂
- 股票代码:
- MDGL
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
524.87 USD (+3.41%)
收盘价
最后更新: 2026年8月17日
10.4B USD
市值
股价为何变动
As of Aug 17, 2026, MDGL closed up 3.41% at $524.87. No new same-company headline was identified in the current news window.
公司概览
Commercial MASH Leader
Madrigal Pharmaceuticals is a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis, or MASH. Its lead product, Rezdiffra, is a once-daily oral liver-directed THR-beta agonist and the first medicine approved by both the FDA and European Commission for MASH with moderate to advanced fibrosis.
Rezdiffra Growth Platform
Rezdiffra is the company's commercial foundation. Second-quarter 2026 net sales reached $364.3 million, up 71% year over year, and more than 49,000 patients were on therapy as of June 30, 2026. Madrigal is investing in field-force expansion, disease education, real-world evidence, and physician adoption to maximize the long-term value of the launch.
Pipeline Anchored by Combination Therapy
Madrigal is building beyond Rezdiffra through MGL-2086, an oral small-molecule GLP-1 receptor agonist and orforglipron derivative. The company initiated Phase 1 dosing in June 2026 as part of a strategy to develop once-daily oral combination treatments for MASH anchored by Rezdiffra.
Strategic Position
Madrigal is best understood as a commercial-stage MASH company with a foundational therapy and a strategy to defend leadership through IP, evidence generation, and combination development. Its differentiation rests on Rezdiffra's first-mover position, expanding patient base, and potential to address both liver and cardiometabolic risk.
未来催化剂
- Phase 1 safety and dose-response evaluation for MGL-2086 after first dosing in June 2026.
- Future data from the Phase 3 outcomes trial of Rezdiffra in compensated MASH cirrhosis.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。